ELA026

Phase 3

TherapeuticsMD, Inc. (TXMD)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

ETRAPhase 3$843M

ELA026 Phase 3 Est. Readout

ELA026• Secondary Hemophagocytic Lymphohistiocytosis (sHLH)156

Jun 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

View Full Landscape

Drug Information

Target Indication

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Clinical Trial

NCT05416307

Last updated: 7/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

TXMD

TherapeuticsMD, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

KarXTPhase 3

Psychosis Associated With Alzheimer's Disease

DexycuPhase 3

Inflammation

enclomiphene citratePhase 3

Effect of Treatment on Bone Mineral Density

REL-1017Phase 3

Major Depressive Disorder

ETC-1002Phase 3

Hypercholesterolemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts